Table 1.
List of LncRNAs whose expression has been down-regulated in the psoriasis.
| LncRNA | Numbers of clinical samples | Source | Targets/Regulators | Signaling Pathways | Function and comments | Reference |
|---|---|---|---|---|---|---|
| MEG3 | 19 cases and 19 controls were recruited in this study. | HaCaT, HHEKs and psoriatic skin samples | Caspase-8, cytc, apaf-1 and miR-21 | MEG3/miR-21 signaling | LncRNA MEG3 affects the proliferation and apoptosis through regulating miR-21 expression and subsequently caspase-8. | [14] |
| AL162231.4 | 30 patients with psoriasis and 28 healthy controls were recruited in this study. | Skin samples | CCL27 | Chemokine signaling pathway, the immune response, epidermal development and skin barrier | The downregulation of LncRNA-AL162231.4 regulates CCL27 expression. | [15] |
| NONHSAT044111 | 15 patients with psoriasis and 15 healthy controls were recruited. | Skin samples | Differentiation and function of Treg cells, NF-κΒ, mTOR, MAPK and JAK-STAT signaling pathway and the release of cytokines and chemokines | The mentioned lncRNAs may be used as potential biomarkers and therapeutic targets for the treatment of psoriasis. | [12] | |
| PPM1N-1:1 | ||||||
| GRHL2-11:1 | ||||||
| JAKMIP2-1:1 | ||||||
| GGTLC1-2:1 | ||||||
| NONHSAT025181 | ||||||
| ENST00000447257 | ||||||
| ENST00000623414 | ||||||
| ENST00000415656 | ||||||
| LINC00273-22:1 |